Feasibility study of PET Imaging with 64Cu-DOTA-trastuzumab in HER2 positive breast cancer

Feasibility study of PET Imaging with 64Cu-DOTA-trastuzumab in HER2 positive breast cancer - PET Imaging with Cu-64 Labeled Trastuzumab

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004170

Enrollment

Registered

2010-09-07

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Patients with invasive ductal carcinoma of breast. 2. HER2 positive (IHC 3+&gt

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Patients with invasive ductal carcinoma of breast. 2. HER2 positive (IHC 3+> or FISH positive) breast cancer 3. Currently taking or about to commence treatment with trastuzumab 4. Age: >20 years, < 75 years 5. ECOG Performance Score 0 or 1. 6. Good main organ function 7. Capability to be received PET scan. 8. Signed informed consent

Exclusion criteria

Exclusion criteria: 8. 1.active concomitant malignancy 2.congestive heart failure (CHF)3.uncontrolled angina pectoris, arrhythmia 4.symptomatic infectious disease 5.severe bleeding 6.pulmonary fibrosis 7.obstructive bowel disease or severe diarrhea 8.symptomatic peripheral or cardiac effusion 9.symptomatic brain metastasis.

Design outcomes

Primary

Measure	Time frame
To find recommend dose and schedule of PET scan for molecular imaging by 64Cu-DOTA-trastuzumab.	—

Secondary

Measure	Time frame
Second objective: To descover the novel molecular imaging to detect HER2 positive tumor inside the body without needle biopsy.	—

Countries

Japan

Contacts

Public ContactKenji Tamura

National Cancer Center Hospital Breast and Medical Oncology div.

ketamura@ncc.go.jp03-3542-2511

Outcome results